Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-31

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). Nerve conduction studies (NCSs) are an essential tool in the evaluation of the peripheral nervous system. The sensory nerve action potential (SNAP) provides information on the sensory nerve axon and its pathway from the distal receptors in the skin to the dorsal root ganglia, while the compound muscle action potential (CMAP) is an assessment of the motor nerve fibers from their origins in the anterior horn cell to their termination along muscle fibers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Examination of Efficacy and Safety of Baricitinib in RA Patients

NCT03755466

Rheumatoid Arthritis

RECRUITING PHASE2

BARIcitinib Cognitive Emotional and Neural signaTuRE

NCT05238896

Rheumatoid Arthritis

TERMINATED PHASE4

Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy

NCT01469013

Arthritis, Rheumatoid

COMPLETED PHASE2

A Study in Moderate to Severe Rheumatoid Arthritis Participants

NCT01721057

Rheumatoid Arthritis

COMPLETED PHASE3

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01711359

Rheumatoid Arthritis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rheumatoid Arthritis patients on Baricitinib treatment

Group Type ACTIVE_COMPARATOR

Nerve Conduction Study

Intervention Type DEVICE

Sensory and Motor Nerve Conduction study on upper and lower limbs.

Rheumatoid Arthritis patient on conventional synthetic DMARD

Group Type ACTIVE_COMPARATOR

Nerve Conduction Study

Intervention Type DEVICE

Sensory and Motor Nerve Conduction study on upper and lower limbs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.